Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT05719116
Active, not recruiting Not applicable

A Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders

NCT05719116 · tracked via the Priya Life Science Norway tracker
Sponsor
Solli Distriktspsykiatriske Senter
Phase
Not applicable
Started
2022-11-23
Last updated
2025-09-24

Condition(s) studied

Psychosis

Investigational drug(s) / intervention(s)

Physical exercise

Physical exercise: The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.

Study summary

The study is a feasibility study of a combined high intensity aerobic and strenght exercise program for persons with psychotic disorders. The feasibility of the protocol will be investigated, in addition to the participants subjective experience with the participation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Participants with psychotic disorder: Inclusion Criteria: * Signed informed consent * Diagnosed with psychotic disorder * Physically able to participate in physical exercise * Is a patient at Solli DPS * Motivated for participating in physical exercise Exclusion Criteria: * Physical conditions precluding the participant from the physical testing/training * Mental state that hinders participation, such as ongoing suicidality, substance abuse or brain organic disorder Participants with psychiatric disorder, but no psychotic disorder: Inclusion Criteria: * Signed informed consent * Diagnosed with psychiatric disorder, but not a psychotic disorder * Physically able to participate in physical exercise * Is a patient at Solli DPS * Motivated for participating in physical exercise Exclusion Criteria: * Physical conditions precluding the participant from the physical testing/training * Mental state that hinders participation, such as ongoing suicidality, substance abuse or brain organic disorder

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Solli DPS Bergen Nesttun

More Solli Distriktspsykiatriske Senter trials in Norway

High Intensity Training for Adults With ADHD in Specialised Mental Health Care Enrolling by invitation
Physical Exercise Augmented CBT for GAD Active, not recruiting
eBehandling - Health and Work for Patients in Specialist Mental Health Care Recruiting

Other trials for the same condition

Virtual Reality and Artificial Intelligence in Treatment for Patients With Psychosis Recruiting
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05719116 on ClinicalTrials.gov ↗ ← All trials in Norway